Gabrielle Agin-Liebes, PhD
Instructor of PsychiatryCards
About
Research
Publications
2026
The association between obsessive-compulsive symptoms and self-compassion: A meta-analysis and systematic review
Shnayder S, Funaro M, Ching T, Pittenger C, Kelmendi B, Adams T, Agin-Liebes G. The association between obsessive-compulsive symptoms and self-compassion: A meta-analysis and systematic review. Journal Of Affective Disorders 2026, 405: 121546. PMID: 41796771, DOI: 10.1016/j.jad.2026.121546.Peer-Reviewed Original ResearchOC symptom severitySelf-CompassionSymptom dimensionsUnacceptable thoughtsSymptom severityMeasures of self-compassionSystematic reviewAssociated with self-compassionOC symptom dimensionsSeverity of psychopathologyObsessive-compulsive symptomsLow self-compassionPeer-reviewed quantitative studiesMeta-analysisCultural orientationOC symptomsFunnel plot symmetryModeration analysisTotal symptomsRandom-effects modelIntervention studiesModerating effectPersonal sufferingPublication biasModerate heterogeneity
2025
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Ching T, Stahnke B, Shnayder S, Agin-Liebes G, Adams T, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D’Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Purohit P, Schaer H, Sierra Y, Witherow C, Pittenger C, Kelmendi B. Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Frontiers In Psychiatry 2025, 16: 1726818. PMID: 41450831, PMCID: PMC12728583, DOI: 10.3389/fpsyt.2025.1726818.Peer-Reviewed Original ResearchObsessive-compulsive disorderObsessive-compulsive disorder symptomsPsilocybin experienceInterpretative phenomenological analysisSubjective effectsTreatment-refractory obsessive-compulsive disorderRandomized placebo-controlled trialSubjective effects of psilocybinEffects of psilocybinEvidence-based psychotherapiesAcute effectsPhenomenological analysisModerate to strong influencePsilocybin doseBehavioral effectsTherapeutic changeHigher-order themesPlacebo-controlled trialPsilocybinNon-directive supportDouble-blindParticipants' perspectivesDisordersAcute interferenceParticipantsPsychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders
Mehtani N, Mian M, Agin-Liebes G, Coker A, Huebner C, Anderson B, Mitchell J. Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders. Journal Of Psychoactive Drugs 2025, ahead-of-print: 1-10. PMID: 41214462, PMCID: PMC12646296, DOI: 10.1080/02791072.2025.2583960.Peer-Reviewed Original ResearchSubstance use disordersUse disorderPsychedelic useMechanisms of behavior changeEffects of psychedelicsStimulant use disorderSubstance use disorder treatmentParticipants' narrativesPsychological distressCommunity-based recoveryPsychosocial Well-BeingPeyote usePilot findingsCommunity-based approachExperiences of participantsBehavioral changesProgram engagementPsychedelicsDisordersCommunity partnersCommunity-BasedRecovery paradigmWell-beingClinical careParticipantsSelf-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder
Agin-Liebes G, Zeifman R, Mitchell J. Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder. European Journal Of Psychotraumatology 2025, 16: 2485513. PMID: 40331914, PMCID: PMC12064107, DOI: 10.1080/20008066.2025.2485513.Peer-Reviewed Original ResearchConceptsMDMA-assisted therapyPosttraumatic stress disorderUncompassionate self-respondingCompassionate self-respondingSevere posttraumatic stress disorderReducing PTSD severitySelf-CompassionPTSD severityStress disorderSelf-kindnessSelf-judgmentDepressive symptomsOver-identificationMeasures of PTSD severitySelf-respondentsCo-occurring disordersSubstance use symptomsSelf-Compassion ScaleCo-occurring depressionAlcohol use disorderSubstance use disordersUse disorderDouble-blind trialPlacebo-controlled trialPsychological mechanismsA Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., ... & Yaden, M. E. (2025). A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Medicine, 3(1), 1-18.Peer-Reviewed Original ResearchA Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Yaden D, Graziosi M, Owen A, Agin-Liebes G, Aaronson S, Allen K, Barrett F, Bogenschutz M, Carhart-Harris R, Ching T, Cosimano M, Danforth A, Davis A, Garcia-Romeu A, Griffiths R, Grob C, Gründer G, Gukasyan N, Heinzerling K, Hendricks P, Holze F, Horton D, Johnson M, Kelmendi B, Peck S, Koslowski M, Liechti M, Mertens L, Moreno F, Nayak S, Nicholas C, Preller K, Rieser N, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk D, Vollenweider F, Weiss B, Wolff M, Yaden M. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Medicine 2025, 3: 1-18. PMID: 40351554, PMCID: PMC12060849, DOI: 10.1089/psymed.2024.0019.Peer-Reviewed Original ResearchResearch settingsSerotonin 2A receptor agonistAcute subjective effectsReflexive thematic analysisPsychological safetyPsychedelic treatmentIdentified themesSerotonergic psychedelicsSubjective effectsPsychological supportThematic analysisMedical staffPsychedelic experienceStates of consciousnessFamily historyPsilocybinReceptor agonistsWell-beingPsilocybin studiesDecades of researchPsychedelicsPsychoeducationPotential contraindicationsLevel of riskAnticipated outcomesPreliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico
Giovannetti, C., Loizaga-Velder, A., Campoy Gomez, R., Ochoa Jaime, G. R., Castillo Valenzuela, T., Sanchez, G., ... & Rush, B. (2025). Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico. Journal of Psychedelic Studies.Peer-Reviewed Original ResearchPreliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico
Giovannetti C, Loizaga-Velder A, Campoy Gomez R, Ochoa Jaime G, Castillo Valenzuela T, Sanchez G, Marcus O, Agin-Liebes G, Rush B. Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico. Journal Of Psychedelic Studies 2025 DOI: 10.1556/2054.2024.00401.Peer-Reviewed Original ResearchBeck Anxiety InventoryComplicated griefAyahuasca ceremoniesMental health programsBDI-IIPsychotherapeutic supportMini International Neuropsychiatric InterviewReducing mental health symptomsPost-traumatic Stress ChecklistInternational Neuropsychiatric InterviewBeck Anxiety Inventory scoresHealth programsSubstance use disordersBeck Depression InventoryBDI-II scoresMental health treatmentMental health symptomsCommunity-based mental health programsOutpatient treatment servicesMental health disordersScores of depressionDSM-5PTSD symptomsShort-term symptom improvementPCL-5
2024
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Petridis P, Grinband J, Agin-Liebes G, Kinslow C, Zeifman R, Bogenschutz M, Griffiths R, Ross S. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nature Mental Health 2024, 2: 1408-1414. DOI: 10.1038/s44220-024-00331-0.Peer-Reviewed Original ResearchPsilocybin-assisted psychotherapyInterpersonal sensitivityObsession-compulsionPsychiatric symptomsPsychiatric symptom dimensionsMental health treatmentPlacebo-controlled crossover trialSymptom dimensionsAnxiety disordersTreating moodHealth treatmentImprove anxietyCancer-related distressAnxietyDepressionPsychotherapyPhobiaPsychosisParanoiaSomatizationHostilityCrossover trialSymptomsMultiple dimensionsClinical improvementPsilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Petridis, P. D., Grinband, J., Agin-Liebes, G., Kinslow, C. J., Zeifman, R. J., Bogenschutz, M. P., ... & Ross, S. (2024). Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nature Mental Health, 2(11), 1408-1414.Peer-Reviewed Original Research
Get In Touch
Contacts
Locations
Temple Medical Center
Academic Office
40 Temple Street
New Haven, CT 06510